Alkermes plc (ALKS) Stock
Key stats
- Market cap
- $7.48B
- Price / Earnings ratio
- -21970.1x
- Volume
- Loading
- 52-week high
- $55.67
- 52-week low
- $27.00
Source: third-party data provider, as of November 7, 2026
Compare with ALKS
Recent news
Alkermes to Present at Upcoming Investor Conferences
Alkermes to Present at Upcoming Investor Conferences
ALKS
What Alkermes (ALKS) Said on Its Q3 Earnings Call
What Alkermes (ALKS) Said on Its Q3 Earnings Call
ALKS
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
ALKS
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
ALKSNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 53.73
- MACD 12/26/9
- 0.67
- EMA 9 of MACD
- 0.36
- MACD histogram
- 0.31
- SMA 50
- $43.77
- Price above SMA 50
- EMA 50
- $44.21
- Price above EMA 50
- SMA 200
- $40.74
- Price above SMA 200
- EMA 200
- $39.73
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.37 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Alkermes to Present at Upcoming Investor Conferences
Alkermes to Present at Upcoming Investor Conferences
ALKSWhat Alkermes (ALKS) Said on Its Q3 Earnings Call
What Alkermes (ALKS) Said on Its Q3 Earnings Call
ALKSAlkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
ALKSAlkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
ALKS
Alkermes plc Reports Third Quarter 2026 Financial Results
Alkermes plc Reports Third Quarter 2026 Financial Results
ALKS
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
ALKS
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes to Report Third Quarter Financial Results on November 3, 2026
ALKS
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
ALKS
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
ALKS
4 CNS Drug Stocks Worth Watching This World Mental Health Day
4 CNS Drug Stocks Worth Watching This World Mental Health Day
ALKSNews tone: automated (AI) classification of the article's content, not a price prediction.
About Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joshua Reed M.B.A. | Senior VP & CFO | 1973 |
| Mr. David Joseph Gaffin J.D. | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 1972 |
| Dr. Craig C. Hopkinson M.D. | Executive VP of Research & Development and Chief Medical Officer | 1969 |
| Mr. Christian Todd Nichols | Senior VP & Chief Commercial Officer | 1970 |
| Mr. Samuel J. Parisi | Interim Principal Accounting Officer & VP of Finance | 1975 |
| Mr. Tom Skoff | SVP & Chief Information Officer | — |
| Ms. Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | — |
| Mr. Stephen Schiavo | Senior VP & Chief Human Resources Officer | — |
| Mr. Peter Norman | SVP of Policy, Government & Community Relations | — |
| Mr. Declan O'Connor | Senior Vice President of Operations and Environment, Health & Safety | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 53.73
- MACD 12/26/9
- 0.67
- EMA 9 of MACD
- 0.36
- MACD histogram
- 0.31
- SMA 50
- $43.77
- Price above SMA 50
- EMA 50
- $44.21
- Price above EMA 50
- SMA 200
- $40.74
- Price above SMA 200
- EMA 200
- $39.73
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $50.00
- Average
- $58.00
- High
- $68.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -25.3 | +8.3 | ||||||||||
| 2022 | +5.6 | -1.6 | +9.9 | +2.8 | +3.4 | -0.6 | -16.1 | -6.0 | -8.3 | -1.1 | +6.6 | +3.7 |
| 2023 | +10.7 | -6.8 | +3.0 | -0.4 | +1.0 | +6.9 | -4.0 | +2.3 | -4.3 | -13.8 | -1.6 | +14.2 |
| 2024 | -5.5 | +10.2 | -10.5 | -9.9 | -2.5 | +0.2 | +12.0 | +5.9 | -0.5 | -10.9 | +9.6 | -2.1 |
| 2025 | +9.7 | +11.6 | -3.2 | -11.6 | +0.1 | -8.6 | -8.6 | +9.1 | +2.0 | +0.2 | -2.0 | -3.2 |
| 2026 | +19.9 | -13.9 | +16.9 | -3.8 | +26.4 | +24.0 | -5.3 | -5.1 | -14.2 | +11.8 | +2.2 |
